Full-Time
Develops FDA-cleared prescription digital therapeutics
$180k - $280k/yr
H1B Sponsorship Available
New York, NY, USA
Hybrid
At least four days in the office each week.
Bachelor's, MBA, PharmD
| , |
See people who can refer or advise you
Click Therapeutics creates prescription software to treat health conditions with digital therapeutics. Its products are software applications that can be used as medicines alone or with traditional treatments, designed to affect cognitive and neurobehavioral processes underlying diseases. They are developed and validated through randomized controlled trials and pursue FDA clearance to market them as class II medical devices. Revenue comes from physicians who prescribe the apps and payers who reimburse them, with real-world evidence used to refine and personalize the software. A notable collaboration with Boehringer Ingelheim aims to develop a $500 million prescription digital therapeutic for schizophrenia. The leadership includes CEO David B. Klein and C-suite officers, with a focus on bringing clinically validated digital health solutions to patients who have unmet medical needs.
Company Size
51-200
Company Stage
Series D
Total Funding
$211.6M
Headquarters
New York City, New York
Founded
2012
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Unlimited Paid Time Off
Flexible Work Arrangement
Stock Options
Performance Bonus
Fertility Treatment Support
Professional Development Budget
Commuter Benefits
Oura welcomes Sanjay Chandra as Chief Information Officer and Han Chiu as SVP of AI and Software Engineering. Oura is pleased to welcome Sanjay Chandra as Chief Information Officer, reporting to Sean Brecker, and Han Chiu as Senior Vice President of AI and Software Engineering, reporting to Michael Chapp. Together, they bring deep experience scaling enterprise technology, software organizations, health technology, and AI-powered product development during periods of significant growth. "Oura has spent more than a decade earning our members' trust with their health data and insights," said Tom Hale. "Scaling that trust to serve millions of people worldwide is a different challenge, one that demands exceptional leaders and durable foundations. I'm proud to welcome Sanjay and Han to Oura. Their experience will help us scale the systems, software, and AI capabilities to grow responsibly while delivering on our mission to help people live longer, healthier lives." Scaling Oura's strong foundation. These appointments reflect an important moment for Oura. As the company continues its evolution from a wearable company into a longitudinal health platform, it is investing in the leadership and infrastructure required to support that ambition, not only through continued innovation, but through privacy, security, responsible AI, interoperability, and enterprise-grade systems. Oura's growth is creating new opportunities to help people understand and improve their health, and a greater responsibility to protect the data and trust at the center of that experience. Data is the foundation of AI at Oura, and the company's governance practices are scaling alongside its product ambitions. Sanjay Chandra: Scaling systems, security, and trust. As Oura's first Chief Information Officer, Sanjay will oversee the enterprise technology foundation required for a health technology platform. His remit includes enterprise AI technology strategy, business-systems transformation, and the systems, infrastructure, and governance needed to help Oura scale responsibly. Sanjay most recently served as Vice President and Global Head of Information Technology at Lucid Motors, where he oversaw go-to-market technologies, enterprise systems, factory systems technologies, global infrastructure, data, and cybersecurity. Before Lucid, he was Chief Information Officer and Head of Cloud Operations at TiVo (acquired by Xperi), responsible for customer success, cloud operations, infrastructure, eCommerce, and corporate IT. Earlier in his career, he held technology leadership roles at Workday and PayPal. Across these roles, Sanjay has helped fast-growing companies scale their technology organizations, operating models, and governance to match their ambitions. At Oura, he will focus on ensuring the company's platform and continued evolution of AI is built on a foundation of security, consent, privacy, and trust. "Technology should be invisible when it works well, but it shapes every part of the customer experience," said Sanjay Chandra, chief information officer at Oura. "In health technology, it must also earn confidence at every step. Oura has an extraordinary opportunity to define what a trusted, AI-enabled health platform can be. I'm excited to help scale the secure, resilient systems and governance that allow Oura to scale responsibly and deliver on its mission for millions of members." Han Chiu: advancing software and AI at Oura. As Senior Vice President of AI and Software Engineering, Han will lead Oura's global software engineering organization across mobile, backend, platform, and AI engineering, while owning the company's software and AI strategy. Han joins Oura from Click Therapeutics, where he served as Chief Technology Officer and led engineering, data, platform, product, and design for FDA-regulated, prescription digital therapeutics operating under HIPAA. During his tenure, Click advanced its AI transformation and delivered FDA-cleared digital treatments validated through randomized controlled trials. Before Click, Han spent two decades leading engineering organizations at American Express, Shutterstock, Namely, and WeWork. Han's experience spans health and consumer technology, as well as the organizational and technical changes required to become more AI-native. At Oura, he will help strengthen engineering execution, evolve how the company architects and scales its platforms, and use AI not only to improve how products are built, but to expand what Oura can create for its members. "AI is expanding both what we can create and how quickly we can bring it to members," said Han Chiu, senior vice president of AI and SWE at Oura. "The opportunity at Oura is to pair that pace with the rigor required to build technology people can trust with their health. Oura has assembled a world-class team and a strong foundation; I'm excited to help turn its ambition into products and experiences that make a meaningful difference in people's lives." Investing in the infrastructure that trust requires. Healthcare is an infrastructure business. As Oura expands across products, channels, geographies, and partnerships, the systems behind the member experience must be reliable, secure, interoperable, and built to support the standards of a health technology platform. That means treating privacy and security as product foundations, evolving governance that enables innovation rather than slows it down, and ensuring that Oura's software, data, and AI capabilities can scale in a way that remains worthy of the trust members place in the company. Sanjay and Han's appointments are part of Oura's broader investment in the leadership required for its next chapter. The company is building not only for continued consumer adoption, but for long-term credibility with members, providers, partners, and institutions. The ambition is simple: to create technology that helps more people live longer, healthier lives, and to scale the systems and safeguards that make that future possible.
Former Novo Nordisk North America chief joins board of US biotech company. Click Therapeutics has appointed Doug Langa, former Novo Nordisk North America executive, to its board of directors. 4 August 2026at 08:55 Try MedWatch for 14 days - and get access to all content. * Continues as a recurring subscription and is billed annually. Can be terminated after 5 months of subscription with 1 month's notice at the end of a month. Minimum price is up to €539.58 excl. VAT corresponding to 7 months of subscription. Right of withdrawal under the Consumer Contracts Act. Read more here. ** Continues as a recurring subscription for 3 months at a time. Minimum price €286.00 excl. VAT. Can be terminated with 1 month's notice at the end of a 3-month period. Right of withdrawal under the Consumer Contracts Act. Read more here.
Ross Muken to become CEO as SOPHiA GENETICS confirms succession plan ahead of Annual meeting. June 10, 2026 Ross Muken SOPHiA GENETICS (Nasdaq: SOPH) has confirmed a previously announced leadership transition that will see President Ross Muken become chief executive officer on July 1, 2026, as the company positions itself for its next phase of growth in AI-driven precision medicine. The leadership changes, which will be presented to shareholders at the company's Annual General Meeting on June 18, follow a multi-year succession planning process overseen by the board of directors. Under the proposed structure, co-founder and current Chief Executive Officer Dr. Jurgi Camblong will transition to Executive Chairman, while current Chairman Troy Cox will remain on the board as a non-executive director. The transition comes at a pivotal stage for SOPHiA GENETICS as healthcare organizations increasingly adopt artificial intelligence and data-driven technologies to improve diagnostics, treatment selection and patient outcomes. The company has built a global network of nearly 1,000 healthcare institutions across more than 75 countries and has analyzed more than 2 million genomic profiles through its SOPHiA DDM platform. Muken, who joined the company in 2021 as chief financial officer, has steadily expanded his responsibilities over the past five years. He was appointed CFO and chief operating officer in 2023 before becoming president in late 2024. Subject to shareholder approval, he will also join the board of directors when he assumes the CEO role. The board cited Muken's combination of operational, financial and strategic experience, as well as his deep familiarity with the business, as key factors in its succession decision. "I am deeply honored by Jurgi and the Board's confidence in me to lead SOPHiA GENETICS at this important moment," Muken said. "Jurgi has built a truly exceptional company with a clear mission, a differentiated platform, and a passionate team dedicated to improving patient outcomes. I am excited to build on that foundation, accelerate our commercial momentum, and continue delivering value for patients, customers, and shareholders alike." Before joining SOPHiA GENETICS, Muken served as CFO and COO of Click Therapeutics and held senior roles at Evercore/ISI Group, Deutsche Bank Securities and Thomas Weisel Partners. His background spans life sciences, healthcare technology, medical devices and pharmaceutical services. The transition also marks a new chapter for Camblong, who co-founded SOPHiA GENETICS in 2011 and has led the company since its inception. Under his leadership, the business evolved from a Swiss startup into a publicly traded healthcare technology company focused on applying artificial intelligence to genomic and multimodal healthcare data. If elected chairman, Camblong will remain a full-time executive focused on technology innovation and long-term strategy while working closely with Muken on the company's commercial and operational growth initiatives. "This transition marks an exciting new chapter, one where I can further contribute strategically at the Board level as we continue to advance our vision of democratizing data-driven medicine at scale," Camblong said. "I look forward to continuing working closely with Ross as he leads the company into its next phase of growth." Cox, who joined the board in 2019 and became chairman in 2020, helped guide the company through several significant milestones, including its Nasdaq initial public offering in 2021 and its subsequent international expansion. Prior to SOPHiA GENETICS, he served as chief executive officer of Foundation Medicine and led the company through its acquisition by Roche. "Succession is one of the most important responsibilities of any Board, and I am proud of the disciplined, multi-year process that has led to today's announcement," Cox said. "Jurgi's founder vision belongs at the Chair, and Ross's strategic, commercial, and operational track record make him the right CEO to scale the business through its next phase of growth." Alongside the executive transition, SOPHiA GENETICS plans to strengthen its governance structure. The company intends to establish a Lead Independent Director position, rotating annually among the chairs of its independent board committees, and will hold executive sessions exclusively for independent directors at each board meeting. The company noted that these measures, combined with an independent board majority and fully independent committees, are designed to support strong oversight as the business continues to scale. The leadership changes underscore SOPHiA GENETICS' focus on balancing continuity and innovation as artificial intelligence becomes increasingly central to healthcare decision-making. With Camblong remaining closely involved in strategy and technology development and Muken taking responsibility for execution and growth, the company is positioning itself to capitalize on growing demand for AI-powered precision medicine solutions across healthcare systems, laboratories and biopharmaceutical organizations worldwide.
The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part of the agreement, Boehringer is transferring responsibility for commercializing CT-155 to Click Therapeutics.
Click Therapeutics closes USD 50m Series D led by Boehringer for prescription digital device. April 9, 2026 New York-based Click Therapeutics has closed a Series D round anchored by a USD 50 million strategic investment from Boehringer Ingelheim, alongside additional dedicated commercial funding, to support the commercialization of CT-155, an investigational prescription digital therapeutic device for the experiential negative symptoms of schizophrenia. The financing accompanies a structural shift in the CT-155 program: Boehringer Ingelheim is transferring full product responsibility - including commercial and marketing authorization rights - to Click. CT-155 was co-developed by the two companies and has not yet received regulatory clearance. Click said proceeds will be directed toward commercialization activities, contingent on US FDA clearance. The Series D follows a Series C strategic investment by Medidata and Dassault Systèmes in 2025, and a USD 52 million Series B in 2021 co-led by H.I.G. BioHealth Partners and Accelmed Partners. CT-155 received US FDA Breakthrough Device Designation in 2024. The completed Phase III CONVOKE trial (NCT05838625) - a randomized, double-blind, 16-week study evaluating CT-155 versus a digital control app as an adjunct to standard antipsychotic therapy - met its primary endpoint. Treatment with CT-155 produced a 6.8-point improvement in negative symptom severity on the CAINS-MAP scale at 16 weeks, compared with 4.2 points in the digital control arm, representing a 62% relative improvement (Cohen's D effect size of -0.36; p=0.0003). Adverse event rates were 8.3% for CT-155 versus 13.4% for the control arm, with no serious adverse events in either group. A follow-on ENSPIRUS study (NCT06791122), led by Boehringer Ingelheim, is generating real-world effectiveness data and remains active. Click's platform produces regulated prescription mobile applications designed to function as the active therapeutic agent rather than as adjunct monitoring tools. The company describes its approach as operating at the intersection of biology and technology, using AI-based adaptive delivery and patient-centric design to encode psychosocial and neurobehavioral intervention techniques at clinical-grade fidelity. The underlying scientific rationale draws on neuroplasticity research and the established efficacy of cognitive behavioral and motivational enhancement therapies, which the platform aims to deliver consistently and at scale. The company holds 63 granted patents and has previously secured US FDA authorization for CT-132, a prescription digital therapeutic for episodic migraine, and Rejoyn, co-developed with Otsuka Pharmaceuticals for adjunctive treatment of major depressive disorder symptoms. Click has also acquired assets from Better Therapeutics, expanding into cardiometabolic disease, and holds a collaboration with Indivior in substance use disorders. David Benshoof Klein, CEO and founder of Click Therapeutics, said the company has spent over a decade building its capabilities in digital therapeutics and is focused on bringing CT-155 to patients following FDA clearance. No information was available in the provided source material on Klein's prior institutional affiliations or whether the company's platform originated from university research. Your email address will not be published. Required fields are marked *